# Vanna Chiarion‐Sileni

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vanna-chiarion-sileni/

## Facts

| Field | Value |
| --- | --- |
| Citations | 62,165 |
| Field | Melanoma and MAPK Pathways |
| h-index | 80 |
| i10-index | 220 |
| Last Known Institution | Casa di Cura Villa Garda |
| OpenAlex ID | https://openalex.org/A5031591368 |
| ORCID iD | https://orcid.org/0000-0001-9191-9124 |
| Works | 453 |

## Researcher papers

- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma](https://scholariq.org/papers/only-pathologic-complete-response-to-neoadjuvant-chemotherapy-improves-2/)
- [Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial](https://scholariq.org/papers/adjuvant-vemurafenib-in-resected-brafv600-mutation-positive-melanoma-brim8-a/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Casa di Cura Villa Garda](https://scholariq.org/institutions/casa-di-cura-villa-garda/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.